Clinical Trial

Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies

Name: Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies — clinical trial record (NCT07312630)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Early Phase 1

View on ClinicalTrials.gov →

Summary

Evaluate the safety, pharmacokinetic (PK) characteristics, and pharmacodynamic (PD) characteristics of LV009 injection in subjects with relapsed/refractory CD19-positive hematologic malignancies.

Trial Details

NCT Number	NCT07312630
Lead Sponsor	PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Conditions	Non-Hodgkin Lymphoma (NHL), Acute Lymphoblastic Leukemia (ALL), Adult
Enrollment	19 participants
Start Date	2025-09-25
Primary Completion	2026-09-25 (estimated)
Study Completion	2027-12-12 (estimated)
Updated on ClinicalTrials.gov	2025-12-31